Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Notification of cessation of securities
Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 3Y - Change of Director’s Interest Notice
Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
First vitiligo patient enrolled in afamelanotide monotherapy study
CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...
Read More
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting - Notice of Meeting & Explanatory Memorandum 2022
CLINUVEL released the formal Notice of Meeting and Explanatory Memorandum for its...
Read More
CLINUVEL confirms AGM date
CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.
Read More
CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...
Read More
Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit
CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...
Read More